Grifols Shares Rise After 3Q Sales Beat Views

Dow Jones11-08

By Maitane Sardon

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division.

Shares traded 4.7% higher on Friday at 11.17 euros, but they are down 28% over the year to date.

The Spanish pharmaceuticals company said total revenue reached 1.79 billion euros ($1.93 billion)in the third quarter, a 12.2% increase on a reported basis. The figure was 2.2% ahead of Visible Alpha consensus.

Adjusted earnings before interest, taxes, depreciation, and amortization rose 26.7% at constant currency to 462 million euros, driven by product mix, lower cost per liter and operational leverage, Grifols said.

The company said it is on track to reach full year revenue of more than 7 billion euros.

"This was a relatively clean set of results, with no negative surprises and perhaps a few positive ones," Berenberg analysts said in a note. "The ongoing bid situation creates a short-term risk for the shares, as should the Brookfield/Grifols family consortium fail to make an offer for the shares then it would be churlish not to expect some short-term share price weakness," they added.

Write to Maitane Sardon at maitane.sardon@wsj.com

(END) Dow Jones Newswires

November 08, 2024 05:40 ET (10:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481124542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481124542","market":"us","top_or_hot":-1,"title":"Grifols Shares Rise After 3Q Sales Beat Views","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Maitane Sardon \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. \n</p>\n<p>\n  Shares traded 4.7% higher on Friday at 11.17 euros, but they are down 28% over the year to date. \n</p>\n<p>\n  The Spanish pharmaceuticals company said total revenue reached 1.79 billion euros ($1.93 billion)in the third quarter, a 12.2% increase on a reported basis. The figure was 2.2% ahead of Visible Alpha consensus. \n</p>\n<p>\n  Adjusted earnings before interest, taxes, depreciation, and amortization rose 26.7% at constant currency to 462 million euros, driven by product mix, lower cost per liter and operational leverage, Grifols said. \n</p>\n<p>\n  The company said it is on track to reach full year revenue of more than 7 billion euros. \n</p>\n<p>\n  \"This was a relatively clean set of results, with no negative surprises and perhaps a few positive ones,\" Berenberg analysts said in a note. \"The ongoing bid situation creates a short-term risk for the shares, as should the <a href=\"https://laohu8.com/S/BN\">Brookfield</a>/Grifols family consortium fail to make an offer for the shares then it would be churlish not to expect some short-term share price weakness,\" they added. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Maitane Sardon at maitane.sardon@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 08, 2024 05:40 ET (10:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grifols Shares Rise After 3Q Sales Beat Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrifols Shares Rise After 3Q Sales Beat Views\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 18:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Maitane Sardon \n\n\n \n\n\n  Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRFS","symbol_name":"基立福","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481124542","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481124542","pubTimestamp":1731062400,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division.Shares traded 4.7% higher on Friday at 11.17 euros, but they are down 28% over the year to date.The Spanish pharmaceuticals company said total revenue reached 1.79 billion euros in the third quarter, a 12.2% increase on a reported basis. The figure was 2.2% ahead of Visible Alpha consensus.Adjusted earnings before interest, taxes, depreciation, and amortization rose 26.7% at constant currency to 462 million euros, driven by product mix, lower cost per liter and operational leverage, Grifols said.The company said it is on track to reach full year revenue of more than 7 billion euros.\"This was a relatively clean set of results, with no negative surprises and perhaps a few positive ones,\" Berenberg analysts said in a note. \"The ongoing bid situation creates a short-term risk for the shares, as should the Brookfield/Gr","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GRFS":"基立福"},"translate_title":"第三季度销售额超出预期后，Grifols股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRFS":0.9},"content_text":"By Maitane Sardon \n\n\n \n\n\n  Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. \n\n\n  Shares traded 4.7% higher on Friday at 11.17 euros, but they are down 28% over the year to date. \n\n\n  The Spanish pharmaceuticals company said total revenue reached 1.79 billion euros ($1.93 billion)in the third quarter, a 12.2% increase on a reported basis. The figure was 2.2% ahead of Visible Alpha consensus. \n\n\n  Adjusted earnings before interest, taxes, depreciation, and amortization rose 26.7% at constant currency to 462 million euros, driven by product mix, lower cost per liter and operational leverage, Grifols said. \n\n\n  The company said it is on track to reach full year revenue of more than 7 billion euros. \n\n\n  \"This was a relatively clean set of results, with no negative surprises and perhaps a few positive ones,\" Berenberg analysts said in a note. \"The ongoing bid situation creates a short-term risk for the shares, as should the Brookfield/Grifols family consortium fail to make an offer for the shares then it would be churlish not to expect some short-term share price weakness,\" they added. \n\n\n \n\n\n  Write to Maitane Sardon at maitane.sardon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 05:40 ET (10:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481124542"}